Cargando…

Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection

BACKGROUND/AIMS: The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients. METHODS: The medical records of 88 treatment-naïve patients who were diagnosed with CHB and received ETV be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Won Gil, Kim, Hong Joo, Choe, Young Gil, Seok, Hyo Sun, Chon, Chang Wook, Cho, Yong Kyun, Kim, Byung Ik, Koh, Young Yool
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415882/ https://www.ncbi.nlm.nih.gov/pubmed/22893870 http://dx.doi.org/10.3350/cmh.2012.18.2.195

Ejemplares similares

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
por: Choi, Han Na, et al.
Publicado: (2015)

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
por: Kim, Hong Joo, et al.
Publicado: (2017)

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
por: Lee, Kyung Jae, et al.
Publicado: (2018)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

Virologic Response and Safety of Tenofovir Versus Entecavir in Treatment-Naïve Chronic Hepatitis B patients
por: Yu, Hyung Min, et al.
Publicado: (2015)

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
por: Jun, Dae Won, et al.
Publicado: (2013)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response
por: Kwon, Dae Hun, et al.
Publicado: (2013)

Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020)

Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail
por: Oh, Hyunwoo, et al.
Publicado: (2022)

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
por: Kim, Young Min, et al.
Publicado: (2018)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
por: Lee, Jaemin, et al.
Publicado: (2016)

Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
por: Park, Ji Won, et al.
Publicado: (2017)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
por: Kim, Jeong Han, et al.
Publicado: (2016)

Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis
por: Jwa, Hye Young, et al.
Publicado: (2016)

Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients
por: Xie, Yan-Di, et al.
Publicado: (2017)

The Effect of Intestinal Permeability and Endotoxemia on the Prognosis of Acute Pancreatitis
por: Koh, Young Yool, et al.
Publicado: (2012)

An evaluation of entecavir treatment among nucleos(t)ide-naïve Moroccan patients with chronic hepatitis B
por: Chakkor, Amal, et al.
Publicado: (2016)

Corrigendum: Efficacy of Real world Entecavir Therapy in Treatment NaïveChronic Hepatitis B Patients
Publicado: (2017)

Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
por: Cho, Ju-Yeon, et al.
Publicado: (2017)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

Entecavir resistance in a patient with treatment-naïve HBV: A case report
por: Marino, Andrea, et al.
Publicado: (2021)

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Kim, Jung Hee, et al.
Publicado: (2016)

Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
por: Choi, HeeKyoung, et al.
Publicado: (2021)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
por: Choe, Won Hyeok, et al.
Publicado: (2019)

Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: A pilot study
por: Du, Qing-Wei, et al.
Publicado: (2013)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
por: Ahn, Sang Hoon, et al.
Publicado: (2013)

Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study
por: Kim, Jihye, et al.
Publicado: (2023)

Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
por: Choe, Jae Young, et al.
Publicado: (2017)

Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life
por: Luo, Jie, et al.
Publicado: (2013)

Comparison of First-year Results of Tenofovir and Entecavir Treatments of Nucleos(t)ide-naive Chronic Hepatitis B Patients with Hepatosteatosis
por: Dogan, Zeynal, et al.
Publicado: (2015)

Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B
por: Hsu, Po-Ke, et al.
Publicado: (2022)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
por: Kim, Chang Wook, et al.
Publicado: (2018)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9edtm742q69vo9ti2e6qtvgutr